Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Gains from Sales and Divestitures: 2014-2025

Historic Gains from Sales and Divestitures for Ptc Therapeutics (PTCT) over the last 7 years, with Sep 2025 value amounting to $1.2 million.

  • Ptc Therapeutics' Gains from Sales and Divestitures rose 29.99% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year increase of 29.99%. This contributed to the annual value of $963,543 for FY2024, which is 4.68% up from last year.
  • As of Q3 2025, Ptc Therapeutics' Gains from Sales and Divestitures stood at $1.2 million, which was up 5.95% from $1.1 million recorded in Q2 2025.
  • Over the past 5 years, Ptc Therapeutics' Gains from Sales and Divestitures peaked at $1.2 million during Q3 2025, and registered a low of $298,982 during Q1 2021.
  • In the last 3 years, Ptc Therapeutics' Gains from Sales and Divestitures had a median value of $920,488 in 2023 and averaged $926,576.
  • Data for Ptc Therapeutics' Gains from Sales and Divestitures shows a peak YoY skyrocketed of 82.33% (in 2023) over the last 5 years.
  • Over the past 5 years, Ptc Therapeutics' Gains from Sales and Divestitures (Quarterly) stood at $335,114 in 2021, then skyrocketed by 50.65% to $504,851 in 2022, then skyrocketed by 82.33% to $920,488 in 2023, then increased by 4.68% to $963,543 in 2024, then climbed by 29.99% to $1.2 million in 2025.
  • Its Gains from Sales and Divestitures stands at $1.2 million for Q3 2025, versus $1.1 million for Q2 2025 and $1.1 million for Q1 2025.